Fresenius Medical Care AG (XTRA: FME)
Health Care · Health Care Providers & Services · DE
€37.90
+1.07% today · -20.6% 1Y
Fresenius Medical Care AG (XTRA: FME) operates in the Health Care Providers & Services industry within the Health Care sector. The company is valued at $11.13B and employs 107,226 people.
Over the last twelve months the share price has lost 20.6%, trading between 34.57 and 47.86.
Tweenvest scores Fresenius Medical Care AG across four factors: quality 77/100, value 85/100, growth 27/100, dividend 85/100. Its strongest factor is value.
FME price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $11.13B
- Revenue (TTM)
- $22.19B
- P/E
- 11.21
- EPS
- 3.34
- Dividend yield
- 4.06%
- Beta (5Y)
- 0.81
- 52-week high
- €47.86
- 52-week low
- €34.57
- Avg volume (3M)
- —
- Shares outstanding
- 265.03M
- Employees
- 107,226
- Next earnings
- —
About Fresenius Medical Care AG
Fresenius Medical Care AG & Co. KGaA operates as a premier international provider of comprehensive dialysis services and related care, with a significant presence in Germany, North America, and numerous other countries. The company delivers essential dialysis treatments, laboratory analyses, and diagnostic services through its extensive network of outpatient dialysis clinics. Complementing its clinical offerings, Fresenius provides necessary materials, patient training, ongoing clinical monitoring, follow-up support, and arranges for the delivery of supplies directly to patients' residences. In the United States, Fresenius extends its services to hospitals, offering contract dialysis care for inpatients suffering from end-stage renal disease (ESRD) and those experiencing acute kidney failure. Beyond services, the company is a key player in the development, manufacturing, and global distribution of a broad spectrum of dialysis products. This portfolio includes items such as polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, specialized solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, Fresenius produces non-dialysis products, including those for acute cardiopulmonary conditions and apheresis. The company further enhances its offerings by developing, acquiring, and in-licensing renal pharmaceuticals, ensuring these medications and other vital supplies reach patients at home or in dialysis clinics. It also provides an array of specialized medical services, covering vascular, cardiovascular, and endovascular care, operating vascular care ambulatory surgery centers, and delivering physician nephrology and cardiology services. Fresenius Medical Care distributes its extensive product range to dialysis clinics, hospitals, and specialized treatment centers via multiple avenues, including direct sales, dedicated local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, the company managed an impressive 4,171 outpatient dialysis clinics across approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was established in 1996 and is headquartered in Bad Homburg, Germany.
- ISIN
- DE0005785802
- Founded
- 1996
- Listed since
- Jul 22, 1998
- Exchange
- XETRA Trading Platform
- Currency
- EUR
Other Health Care Providers & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| BrightSpring Health Services, Inc.NasdaqGS: BTSG | $13.29B | $62.93 | -1.27% |
| Encompass Health CorporationNYSE: EHC | $12.17B | $125.98 | +2.14% |
| Apollo Hospitals Enterprise LimitedNSEI: APOLLOHOSP | $11.93B | Rs8,027.50 | -1.30% |
| DaVita Inc.NYSE: DVA | $11.43B | $181.71 | +1.37% |
| Aier Eye Hospital Group Co., Ltd.SZSE: 300015 | $10.93B | CN¥7.90 | +0.51% |
| Universal Health Services, Inc.NYSE: UHS | $10.45B | $180.49 | +1.77% |
| Molina Healthcare, Inc.NYSE: MOH | $10.26B | $203.67 | +3.42% |
| The Ensign Group, Inc.NasdaqGS: ENSG | $9.93B | $174.85 | +1.78% |
Figures last refreshed Oct 11, 2026.